(2S,3R)-N-[(3-fluorophenyl)methyl]-3-methoxy-2-[(1-methylpyrazol-4-yl)methyl]pyrrolidine-1-carboxamide
C18H23FN4O2 — CID 97411821
Data last refreshed: (MolForge compound catalog, from PubChem)
About (2S,3R)-N-[(3-fluorophenyl)methyl]-3-methoxy-2-[(1-methylpyrazol-4-yl)methyl]pyrrolidine-1-carboxamide
(2S,3R)-N-[(3-fluorophenyl)methyl]-3-methoxy-2-[(1-methylpyrazol-4-yl)methyl]pyrrolidine-1-carboxamide (PubChem CID 97411821) has the molecular formula C18H23FN4O2 and a molecular weight of 346.41 g/mol. Its IUPAC name is (2S,3R)-N-[(3-fluorophenyl)methyl]-3-methoxy-2-[(1-methylpyrazol-4-yl)methyl]pyrrolidine-1-carboxamide.
Molecular Properties
| Compound Name | (2S,3R)-N-[(3-fluorophenyl)methyl]-3-methoxy-2-[(1-methylpyrazol-4-yl)methyl]pyrrolidine-1-carboxamide |
|---|---|
| PubChem CID | 97411821 |
| Molecular Formula | C18H23FN4O2 |
| Molecular Weight | 346.41 g/mol |
| Exact Mass | 346.18 |
| IUPAC Name | (2S,3R)-N-[(3-fluorophenyl)methyl]-3-methoxy-2-[(1-methylpyrazol-4-yl)methyl]pyrrolidine-1-carboxamide |
| SMILES | CO[C@@H]1CCN(C(=O)NCc2cccc(F)c2)[C@H]1Cc1cnn(C)c1 |
| InChI | InChI=1S/C18H23FN4O2/c1-22-12-14(11-21-22)9-16-17(25-2)6-7-23(16)18(24)20-10-13-4-3-5-15(19)8-13/h3-5,8,11-12,16-17H,6-7,9-10H2,1-2H3,(H,20,24)/t16-,17+/m0/s1 |
| InChIKey | VAZYMUQQTLCERK-DLBZAZTESA-N |
| XLogP | 2.10 |
| TPSA | 59.39 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 25 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 346.41 |
| LogP ≤ 5 | 2.10 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 4 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 97411821 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.